Indeed, the inhibition of glycogen synthase kinase 3 (GSK3) can induce the growth arrest of leukemia cells in KMT2Ar leukemia [78], while targeting the DNA damage response (DDR) pathway can lead to specific synthetic lethality in leukemic cells with MLL-rearrangements [79]. This evidence concerns the gene KMT2A and leukemia.